The primary objective of the Whitehead lab is the development and early clinical evaluation of vaccines for arboviruses. Our comprehensive approach encompasses a bench-to-bedside research program involving vaccine discovery and the generation of recombinant live attenuated viruses that can be pre-clinically studied in mice, nonhuman primates, and mosquitoes before they undergo cGMP manufacture and evaluation in human clinical trials. Support of this vaccine pipeline requires research to understand the mechanisms of virus attenuation and immune presentation, as well as research to support new methods to evaluate immune responses following vaccination or infection.
Stephen S. Whitehead, Ph.D.
Senior Investigator, Arbovirus Vaccine Research Section
Contact: For contact information, search the NIH Enterprise Directory.
Education:
Ph.D., 1994, Oregon State University, Corvallis, OR
Emerito Amaro-Carambot, B.Sc.
Biologist
Contact: For contact information, search the NIH Enterprise Directory.
Education:
B.S., 2001, Microbiology, University of Puerto Rico, Humacao, Puerto Rico
Languages Spoken: Spanish
Elaine Lamirande, B.Sc.
Biologist
Contact: For contact information, search the NIH Enterprise Directory.
Education:
B.S., 1989, Zoology, Duke University, Durham, NC
Saurabh Kumar, M.S., Ph.D.
Postdoctoral Visiting Fellow
Contact: For contact information, search the NIH Enterprise Directory.
Education:
Ph.D., 2019, Microbiology and Cell Biology, Indian Institute of Science, Bangalore, India
M.S., 2010, Molecular Biology and Biotechnology, Tezpur University, Assam, India
Languages Spoken: Hindi, Assamese
William Stone, B.S.
Predoctoral Fellow
Contact: For contact information, search the NIH Enterprise Directory.
Education:
B.S., 2019, Biochemistry and Microbiology, Virginia Polytechnic and State University, Blacksburg, VA
